PubMed HealthSearch

PubMed · 9318589

Ventilatory and blood acid-base adjustments to a decrease in body temperature from 30 to 10YC in black racer snakes Coluber constrictor

Abstract

There is increasing evidence that many amphibian and reptilian species use relatively slow ion-exchange mechanisms in addition to ventilation to adjust pH as body temperature changes. Large changes in blood bicarbonate concentration with changes in temperature have previously been reported for the snake Coluber constrictor. The purpose of the present study was to determine the ventilatory and pH adjustments associated with the increase in CO2 stores when the snakes are cooled. Body temperature was lowered from 30 to 10 °C within 4 h, at which time measurements of inspired minute ventilation (V.air), O2 consumption (VO2) and CO2 production (V.CO2) were started and continued for 56 h. The decrease in temperature produced a transient fall in the respiratory exchange ratio (V.CO2/VO2) to 0.2-0.3 and a steady-state value of 0.65±0.14 (mean ± s.d., N=7) was not achieved until about 35 h. There were concomitant transient reductions in V.air and V.air/V.O2. However, V.air/V.CO2 initially increased, with a corresponding reduction in arterial PCO2 (PaCO2) and increase in arterial pH. By 35 h, V.air/V.CO2 had decreased and PaCO2 had increased to steady-state levels, but pH decreased very little because of a gradual increase in bicarbonate concentration. We conclude that the drop in temperature imposed a metabolic acidosis for approximately 35 h because of the time required to increase bicarbonate concentration, and that the acidosis was compensated for by an elevated V.air/V.CO2. Steady-state breathing and acid-base status were not achieved until the relatively slow increase in CO2 stores had been completed.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Stinner, M Grguric, S Beaty. 1996. Ventilatory and blood acid-base adjustments to a decrease in body temperature from 30 to 10YC in black racer snakes Coluber constrictor. https://doi.org/10.1242/jeb.199.4.815

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article